Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2019
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2019, provides an overview of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline landscape.
Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the blood stream and spread to the other parts of the body. Symptoms for AML include fatigue, fever, bleeding, breathing problems, weight loss. The predisposing factors involved are exposure to radiation or chemicals and smoking. Treatment includes chemotherapy, transfusions, transplant and surgery.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 1, 18, 131, 123, 2, 8, 219, 34 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 16, 18, 3, 1, 43 and 27 molecules, respectively.
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2019, provides an overview of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline landscape.
Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the blood stream and spread to the other parts of the body. Symptoms for AML include fatigue, fever, bleeding, breathing problems, weight loss. The predisposing factors involved are exposure to radiation or chemicals and smoking. Treatment includes chemotherapy, transfusions, transplant and surgery.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 1, 18, 131, 123, 2, 8, 219, 34 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 16, 18, 3, 1, 43 and 27 molecules, respectively.
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Overview
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Development
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Assessment
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Companies Involved in Therapeutics Development
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Drug Profiles
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Product Development Milestones
Appendix
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Overview
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Development
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Assessment
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Companies Involved in Therapeutics Development
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Drug Profiles
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Product Development Milestones
Appendix
LIST OF TABLES
Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by 4SC AG, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AB Science SA, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AbbVie Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ABL Bio Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Actinium Pharmaceuticals Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ADC Therapeutics SA, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Adlai Nortye Biopharma Co Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Advanced BioDesign, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Advenchen Laboratories LLC, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aeglea BioTherapeutics Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Affichem SA, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Agios Pharmaceuticals Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AI Therapeutics, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aileron Therapeutics Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AIMM Therapeutics BV, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aleta Biotherapeutics Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AlfaSigma SpA, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Allogene Therapeutics Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Amgen Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Amphivena Therapeutics Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Amplia Therapeutics Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Angiocrine Bioscience Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Anhui Anke Biotechnology (Group) Co Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ANP Technologies Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Antisense Therapeutics Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AnyGen Co Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by APIM Therapeutics AS, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aprea Therapeutics AB, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AptaBio Therapeutics Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aptevo Therapeutics Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aptose Biosciences Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aravive Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arcellx Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Argenx SE, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arog Pharmaceuticals Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arrien Pharmaceuticals LLC, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arvinas Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ascentage Pharma Group International, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aslan Pharmaceuticals Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Astellas Pharma Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Astex Pharmaceuticals Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AstraZeneca Plc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Atara Biotherapeutics Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Athenex Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ATP Biopharm, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AUM Biosciences Pte Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Auransa Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aurigene Discovery Technologies Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AVEO Oncology Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Avidin Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AVROBIO Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Avvinity Therapeutics Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bantam Pharmaceutical LLC, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bayer AG, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BCI Pharma SA, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Beam Therapeutics Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Beijing Immunochina Medical Science & Technology Co Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bellicum Pharmaceuticals Inc, H2 2019
Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by 4SC AG, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AB Science SA, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AbbVie Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ABL Bio Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Actinium Pharmaceuticals Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ADC Therapeutics SA, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Adlai Nortye Biopharma Co Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Advanced BioDesign, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Advenchen Laboratories LLC, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aeglea BioTherapeutics Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Affichem SA, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Agios Pharmaceuticals Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AI Therapeutics, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aileron Therapeutics Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AIMM Therapeutics BV, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aleta Biotherapeutics Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AlfaSigma SpA, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Allogene Therapeutics Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Amgen Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Amphivena Therapeutics Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Amplia Therapeutics Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Angiocrine Bioscience Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Anhui Anke Biotechnology (Group) Co Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ANP Technologies Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Antisense Therapeutics Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AnyGen Co Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by APIM Therapeutics AS, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aprea Therapeutics AB, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AptaBio Therapeutics Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aptevo Therapeutics Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aptose Biosciences Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aravive Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arcellx Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Argenx SE, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arog Pharmaceuticals Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arrien Pharmaceuticals LLC, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arvinas Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ascentage Pharma Group International, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aslan Pharmaceuticals Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Astellas Pharma Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Astex Pharmaceuticals Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AstraZeneca Plc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Atara Biotherapeutics Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Athenex Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ATP Biopharm, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AUM Biosciences Pte Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Auransa Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aurigene Discovery Technologies Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AVEO Oncology Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Avidin Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AVROBIO Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Avvinity Therapeutics Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bantam Pharmaceutical LLC, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bayer AG, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BCI Pharma SA, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Beam Therapeutics Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Beijing Immunochina Medical Science & Technology Co Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bellicum Pharmaceuticals Inc, H2 2019
LIST OF FIGURES
Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
COMPANIES MENTIONED
4SC AG
A. Menarini Industrie Farmaceutiche Riunite Srl
AB Science SA
AbbVie Inc
ABL Bio Inc
Actinium Pharmaceuticals Inc
ADC Therapeutics SA
Adlai Nortye Biopharma Co Ltd
Advanced BioDesign
Advenchen Laboratories LLC
Aeglea BioTherapeutics Inc
Affichem SA
Agios Pharmaceuticals Inc
AI Therapeutics
Aileron Therapeutics Inc
AIMM Therapeutics BV
Aleta Biotherapeutics Inc
AlfaSigma SpA
Allogene Therapeutics Inc
Amgen Inc
Amphivena Therapeutics Inc
Amplia Therapeutics Ltd
Angiocrine Bioscience Inc
Anhui Anke Biotechnology (Group) Co Ltd
ANP Technologies Inc
Antisense Therapeutics Ltd
AnyGen Co Ltd
APIM Therapeutics AS
Aprea Therapeutics AB
AptaBio Therapeutics Inc
Aptevo Therapeutics Inc
Aptose Biosciences Inc
Aravive Inc
Arcellx Inc
Argenx SE
Arog Pharmaceuticals Inc
Arrien Pharmaceuticals LLC
Arvinas Inc
Ascentage Pharma Group International
Aslan Pharmaceuticals Ltd
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Atara Biotherapeutics Inc
Athenex Inc
ATP Biopharm
AUM Biosciences Pte Ltd
Auransa Inc
Aurigene Discovery Technologies Ltd
AVEO Oncology Inc
Avidin Ltd
AVROBIO Inc
Avvinity Therapeutics Ltd
Bantam Pharmaceutical LLC
Bayer AG
BCI Pharma SA
Beam Therapeutics Inc
Beijing Immunochina Medical Science & Technology Co Ltd
Bellicum Pharmaceuticals Inc
BerGenBio ASA
Betta Pharmaceuticals Co Ltd
Bio-Cancer Treatment International Ltd
Bio-Path Holdings Inc
Biokine Therapeutics Ltd
BioLineRx Ltd
BioMed Valley Discoveries Inc
Bionetix Inc
Bionomics Ltd
BioSight Ltd
BioTheryX Inc
BioXcel Therapeutics Inc
BiVictriX Therapeutics Ltd
bluebird bio Inc
Blueprint Medicines Corp
Boehringer Ingelheim International GmbH
Boryung ViGenCell Inc
Boston Biomedical Inc
BoYen Therapeutics Inc
Bristol-Myers Squibb Co
Canqura Oncology AB
Cantargia AB
Carrick Therapeutics UK Ltd
Catalent Inc
Celgene Corp
CellCentric Ltd
Cellectis SA
Cellerant Therapeutics Inc
Cellipse SAS
Cellular Biomedicine Group Inc
Celularity Inc
Celyad SA
Centrose LLC
Changzhou Qianhong Bio-Pharma Co Ltd
CharlestonPharma LLC
Checkpoint Therapeutics Inc
Chimerix Inc
Chordia Therapeutics Inc
Chugai Pharmaceutical Co Ltd
Clear Creek Bio Inc
Cleave Therapeutics Inc
Constellation Pharmaceuticals Inc
ConverGene LLC
CRISPR Therapeutics AG
CrystalGenomics Inc
CSPC Pharmaceutical Group Ltd
CuronBiotech Inc
Cyclacel Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Dalriada Therapeutics Inc
DC Prime BV
Deciphera Pharmaceuticals Inc
Delta-Fly Pharma Inc
Demuris Ltd
Denovo Biopharma LLC
DiNonA Inc
Dong-A ST Co Ltd
Eli Lilly and Co
Emercell SAS
Eminent Biosciences
EntreChem SL
Epigene Therapeutics Inc
Epizyme Inc
Escend Pharmaceuticals Inc
ExCellThera Inc
Exelixis Inc
Exonate Ltd
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Flavocure Biotech LLC
Forma Therapeutics Inc
Formula Pharmaceuticals Inc
Fortress Biotech Inc
Forty Seven Inc
Fujifilm Holdings Corp
Gadeta BV
Gamida Cell Ltd
GC Pharma
GEMoaB Monoclonals GmbH
Genentech Inc
Genosco Inc
Genus Oncology LLC
Geron Corp
GlaxoSmithKline Plc
GlycoMimetics Inc
Glycostem Therapeutics BV
GO Therapeutics Inc
Golden Biotechnology Corp
GT Biopharma Inc
H3 Biomedicine Inc
Hanmi Pharmaceuticals Co Ltd
Hebei Senlang Biotechnology Inc Ltd
HEC Pharm Co Ltd
Hefei Cosource Pharmaceutical Inc
Helocyte Biosciences Inc
HemoGenyx LLC
HighPass Bio Inc
Hinova Pharmaceuticals Inc
Hoverink Biotechnologies Inc
HRAIN Biotechnology Co Ltd
Hummingbird Bioscience Pte Ltd
Hybrigenics SA
I-Mab Biopharma Co Ltd
iCell Gene Therapeutics LLC
IGF Oncology LLC
IGM Biosciences Inc
Imago BioSciences Inc
Immune Onc Therapeutics Inc
Immune System Key Ltd
ImmunoGen Inc
Immunomedics Inc
Inatherys
Incuron LLC
Incysus Therapeutics Inc
Incyte Corp
Inflection Biosciences Ltd
Inmune Bio Inc
Innovation Pharmaceuticals Inc
Intellia Therapeutics Inc
Interprotein Corp
Intra-Immusg Pvt Ltd
Io Therapeutics Inc
Iovance Biotherapeutics Inc
Iterion Therapeutics
Jay Pharma Inc
Jazz Pharmaceuticals Plc
Jeil Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
JSK Therapeutics Inc
Jubilant Biosys Ltd
Juno Therapeutics Inc
Juventas Cell Therapy Ltd
JW Pharmaceutical Corp
Kainos Medicine Inc
Kartos Therapeutics Inc
Karyopharm Therapeutics Inc
Keystone Nano Inc
Kiadis Pharma NV
KinaRx LLC
KisoJi Biotechnology Inc
Komipharm International Co Ltd
Konruns Pharmaceutical Co Ltd
Kura Oncology Inc
Kymera Therapeutics LLC
Laekna Therapeutics Shanghai Co Ltd
Lai Corporation Pty Ltd
Lead Discovery Center GmbH
Les Laboratoires Servier SAS
Leukos Biotech SL
Lineage Cell Therapeutics Inc
Machavert Pharmaceuticals LLC
MacroGenics Inc
Magenta Therapeutics Inc
Mana Therapeutics Inc
Marker Therapeutics Inc
Mateon Therapeutics Inc
MaxCyte Inc
Maxinovel Pharmaceuticals
MedAbome Inc
MediGene AG
Medivir AB
MEI Pharma Inc
Merck & Co Inc
Merck KGaA
Merus NV
Meryx Inc
Millennium Pharmaceuticals Inc
Minneamrita Therapeutics LLC
Miragen Therapeutics Inc
MiRx Pharmaceuticals LLC
Molecular Templates Inc
Molecules For Health Inc
Moleculin Biotech LLC
MolMed SpA
Mustang Bio Inc
MyeloRx LLC
Nanjing Legend Biotech Co Ltd
Nanjing Sanhome Pharmaceutical Co Ltd
Nanovalent Pharmaceuticals Inc
NantKwest Inc
Nemucore Medical Innovations Inc
Newave Pharmaceutical Inc
NewLink Genetics Corp
NexImmune Inc
Nkarta Inc
NMS Group SpA
Nohla Therapeutics Inc
Northlake International LLC
Novartis AG
OHM Oncology
Omeros Corp
Oncoceutics Inc
Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
COMPANIES MENTIONED
4SC AG
A. Menarini Industrie Farmaceutiche Riunite Srl
AB Science SA
AbbVie Inc
ABL Bio Inc
Actinium Pharmaceuticals Inc
ADC Therapeutics SA
Adlai Nortye Biopharma Co Ltd
Advanced BioDesign
Advenchen Laboratories LLC
Aeglea BioTherapeutics Inc
Affichem SA
Agios Pharmaceuticals Inc
AI Therapeutics
Aileron Therapeutics Inc
AIMM Therapeutics BV
Aleta Biotherapeutics Inc
AlfaSigma SpA
Allogene Therapeutics Inc
Amgen Inc
Amphivena Therapeutics Inc
Amplia Therapeutics Ltd
Angiocrine Bioscience Inc
Anhui Anke Biotechnology (Group) Co Ltd
ANP Technologies Inc
Antisense Therapeutics Ltd
AnyGen Co Ltd
APIM Therapeutics AS
Aprea Therapeutics AB
AptaBio Therapeutics Inc
Aptevo Therapeutics Inc
Aptose Biosciences Inc
Aravive Inc
Arcellx Inc
Argenx SE
Arog Pharmaceuticals Inc
Arrien Pharmaceuticals LLC
Arvinas Inc
Ascentage Pharma Group International
Aslan Pharmaceuticals Ltd
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Atara Biotherapeutics Inc
Athenex Inc
ATP Biopharm
AUM Biosciences Pte Ltd
Auransa Inc
Aurigene Discovery Technologies Ltd
AVEO Oncology Inc
Avidin Ltd
AVROBIO Inc
Avvinity Therapeutics Ltd
Bantam Pharmaceutical LLC
Bayer AG
BCI Pharma SA
Beam Therapeutics Inc
Beijing Immunochina Medical Science & Technology Co Ltd
Bellicum Pharmaceuticals Inc
BerGenBio ASA
Betta Pharmaceuticals Co Ltd
Bio-Cancer Treatment International Ltd
Bio-Path Holdings Inc
Biokine Therapeutics Ltd
BioLineRx Ltd
BioMed Valley Discoveries Inc
Bionetix Inc
Bionomics Ltd
BioSight Ltd
BioTheryX Inc
BioXcel Therapeutics Inc
BiVictriX Therapeutics Ltd
bluebird bio Inc
Blueprint Medicines Corp
Boehringer Ingelheim International GmbH
Boryung ViGenCell Inc
Boston Biomedical Inc
BoYen Therapeutics Inc
Bristol-Myers Squibb Co
Canqura Oncology AB
Cantargia AB
Carrick Therapeutics UK Ltd
Catalent Inc
Celgene Corp
CellCentric Ltd
Cellectis SA
Cellerant Therapeutics Inc
Cellipse SAS
Cellular Biomedicine Group Inc
Celularity Inc
Celyad SA
Centrose LLC
Changzhou Qianhong Bio-Pharma Co Ltd
CharlestonPharma LLC
Checkpoint Therapeutics Inc
Chimerix Inc
Chordia Therapeutics Inc
Chugai Pharmaceutical Co Ltd
Clear Creek Bio Inc
Cleave Therapeutics Inc
Constellation Pharmaceuticals Inc
ConverGene LLC
CRISPR Therapeutics AG
CrystalGenomics Inc
CSPC Pharmaceutical Group Ltd
CuronBiotech Inc
Cyclacel Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Dalriada Therapeutics Inc
DC Prime BV
Deciphera Pharmaceuticals Inc
Delta-Fly Pharma Inc
Demuris Ltd
Denovo Biopharma LLC
DiNonA Inc
Dong-A ST Co Ltd
Eli Lilly and Co
Emercell SAS
Eminent Biosciences
EntreChem SL
Epigene Therapeutics Inc
Epizyme Inc
Escend Pharmaceuticals Inc
ExCellThera Inc
Exelixis Inc
Exonate Ltd
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Flavocure Biotech LLC
Forma Therapeutics Inc
Formula Pharmaceuticals Inc
Fortress Biotech Inc
Forty Seven Inc
Fujifilm Holdings Corp
Gadeta BV
Gamida Cell Ltd
GC Pharma
GEMoaB Monoclonals GmbH
Genentech Inc
Genosco Inc
Genus Oncology LLC
Geron Corp
GlaxoSmithKline Plc
GlycoMimetics Inc
Glycostem Therapeutics BV
GO Therapeutics Inc
Golden Biotechnology Corp
GT Biopharma Inc
H3 Biomedicine Inc
Hanmi Pharmaceuticals Co Ltd
Hebei Senlang Biotechnology Inc Ltd
HEC Pharm Co Ltd
Hefei Cosource Pharmaceutical Inc
Helocyte Biosciences Inc
HemoGenyx LLC
HighPass Bio Inc
Hinova Pharmaceuticals Inc
Hoverink Biotechnologies Inc
HRAIN Biotechnology Co Ltd
Hummingbird Bioscience Pte Ltd
Hybrigenics SA
I-Mab Biopharma Co Ltd
iCell Gene Therapeutics LLC
IGF Oncology LLC
IGM Biosciences Inc
Imago BioSciences Inc
Immune Onc Therapeutics Inc
Immune System Key Ltd
ImmunoGen Inc
Immunomedics Inc
Inatherys
Incuron LLC
Incysus Therapeutics Inc
Incyte Corp
Inflection Biosciences Ltd
Inmune Bio Inc
Innovation Pharmaceuticals Inc
Intellia Therapeutics Inc
Interprotein Corp
Intra-Immusg Pvt Ltd
Io Therapeutics Inc
Iovance Biotherapeutics Inc
Iterion Therapeutics
Jay Pharma Inc
Jazz Pharmaceuticals Plc
Jeil Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
JSK Therapeutics Inc
Jubilant Biosys Ltd
Juno Therapeutics Inc
Juventas Cell Therapy Ltd
JW Pharmaceutical Corp
Kainos Medicine Inc
Kartos Therapeutics Inc
Karyopharm Therapeutics Inc
Keystone Nano Inc
Kiadis Pharma NV
KinaRx LLC
KisoJi Biotechnology Inc
Komipharm International Co Ltd
Konruns Pharmaceutical Co Ltd
Kura Oncology Inc
Kymera Therapeutics LLC
Laekna Therapeutics Shanghai Co Ltd
Lai Corporation Pty Ltd
Lead Discovery Center GmbH
Les Laboratoires Servier SAS
Leukos Biotech SL
Lineage Cell Therapeutics Inc
Machavert Pharmaceuticals LLC
MacroGenics Inc
Magenta Therapeutics Inc
Mana Therapeutics Inc
Marker Therapeutics Inc
Mateon Therapeutics Inc
MaxCyte Inc
Maxinovel Pharmaceuticals
MedAbome Inc
MediGene AG
Medivir AB
MEI Pharma Inc
Merck & Co Inc
Merck KGaA
Merus NV
Meryx Inc
Millennium Pharmaceuticals Inc
Minneamrita Therapeutics LLC
Miragen Therapeutics Inc
MiRx Pharmaceuticals LLC
Molecular Templates Inc
Molecules For Health Inc
Moleculin Biotech LLC
MolMed SpA
Mustang Bio Inc
MyeloRx LLC
Nanjing Legend Biotech Co Ltd
Nanjing Sanhome Pharmaceutical Co Ltd
Nanovalent Pharmaceuticals Inc
NantKwest Inc
Nemucore Medical Innovations Inc
Newave Pharmaceutical Inc
NewLink Genetics Corp
NexImmune Inc
Nkarta Inc
NMS Group SpA
Nohla Therapeutics Inc
Northlake International LLC
Novartis AG
OHM Oncology
Omeros Corp
Oncoceutics Inc
